Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 5 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophre
Referring a patient is easy. Just click the “Refer a Patient Online” button.
Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 5 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophre
Referring a patient is easy. Just click the “Refer a Patient Online” button.
Latest Articles
Psychiatry Specialty Report 2022
In addition to launching three centers, we were ranked No. 7 in National Institutes of Health (NIH) funding for psychiatry, published more than 850 papers, completed more than 800,000 outpatient visits, and received $49 million in active grants.
Road to Resilience Podcast: The Therapeutic Promise of Psychedelics
Listen or read the transcript of this informative podcast with Rachel Yehuda, PhD, on the potential of MDMA to treat patients with post-traumatic stress disorder
Two Faculty Members Receive Endowed Professorships in 2021
In 2021, two professors from the Department of Psychiatry received Mount Sinai's highest honors in academic medicine: Rita Goldstein, PhD, and Rachel Yehuda, PhD.
Atypical Psychosis and the Value of an Individualized Approach
Clinicians were challenged to successfully treat a young man who appeared to have acute psychosis, but it turned out to be a rare form of stroke.
Cerebral Organoids Provide a Vivid Window into the Brain
For the first time, stem cell-derived organoid models are allowing scientists to study the cellular development and intercellular interactions among microglia and other cell types within a 3D human brain microenvironment.
A Popular Program Helps Employees Build Resilience and Serves as a National Model
Mount Sinai's Center for Stress, Resilience and Personal Growth was created to help frontline health workers cope with the psychosocial trauma of the COVID-19 pandemic.
New Discoveries in the Use of Ketamine for Post-Traumatic Stress Disorder
Mount Sinai continues to gain global recognition for its groundbreaking work with ketamine and post-traumatic stress disorder (PTSD).
A Robust Pipeline of Physician-Scientist Training Programs
Mount Sinai's Department of Psychiatry provides residents and fellows with the resources and support they need to turn patient experience into valuable research so they can become fluent in both science and medicine.
Ensuring Diversity, Equity, and Inclusion Within the Department of Psychiatry
The Department of Psychiatry is training students, residents, and fellows on the issues of social justice and diversity and working toward the elimination of race-based discrepancies in the diagnosis and treatment of patients.
The unique pairing of the Nash Family Center for Advanced Circuit Therapeutics and the Center for Computational Psychiatry is generating some of the nation's most advanced research into the brain.
Genomics-Driven Clinical Research Focused on Adolescent Psychiatric Disorders
An estimated three-quarters of all psychiatric disorders debut prior to or during adolescence. To address this, in October 2021, Mount Sinai established the Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment.
Brian Sweis, MD, PhD: A Physician-Scientist’s Approach to Psychiatry
Scientists trained as physicians, like Dr. Sweis, are in a unique position to understand and enhance the links between preclinical research and clinical applications in humans to advance patient treatments. Read about his path, and where he plans to go next.
New Center for Computational Psychiatry
Since its inception in the early 2010s, computational psychiatry has become one of the fastest growing and most exciting areas in neuropsychiatry
New Approach to Treating Depression: KCNQ2/3 Channel
Initial evidence in humans for the KCNQ2/3 channel as a new target for novel drug discovery for depression and anhedonia
Mount Sinai Health System Launches Center for Psychedelic Research
New research center will focus on studying MDMA, psilocybin, and other psychedelic compounds to treat post-traumatic stress disorder, depression, and other psychological conditions
Psychiatry Specialty Report 2021
As a response to COVID-19, we created a Center for Stress, Resilience, and Personal Growth to provide mental health services to our staff, faculty, students, and trainees. Services include individualized assessments, planning, and coaching; ...
Five Things to Know About Providing Psychiatric Care to COVID-19 Heath Care Workers
Health care workers will likely be facing significant mental health consequences due to their involvement with COVID-19. Check out the top five things to know about providing psychiatric care to these health care workers during and after the pandemic.
COVID-19 and Employee Mental Health: A Five-Tier Model of Support
New York City is an epicenter of COVID-19 pandemic in the United States, and the Mount Sinai Health System has spearheaded an array of clinical and organizational innovations to mitigate the crisis.
Five Things to Know About Esketamine
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, ...
Five Things to Know About MDMA-Assisted Psychotherapy for PTSD
MDMA, the psychoactive drug sometimes known as ecstasy, is poised to become a powerful tool in the treatment of PTSD. In 2017, the U.S. Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy.
Latest Videos
René Kahn, MD, PhD: Tackling the Neurobiology of Schizophrenia
Dr. Kahn discusses how brain changes in schizophrenic patients are related to disease progression and outcomes.
From Party to Prescription: How Psychedelics Are Changing Traditional Psychiatry
Listen as Mount Sinai neuroscientists discuss ketamine, cannabis, and ecstasy as potential treatments for treatment-resistant depression, opioid addiction, and post-traumatic stress disorder
How Epidemics Affect Our Mental Health
Craig Katz, MD, Director of Mount Sinai’s Global Mental Health Program, delivers a Grand Rounds presentation on the behavioral sequelae of epidemics.
How to Use Psychological First Aid to Prevent Post-Disaster Psychopathology
Craig Katz, MD, Director of Mount Sinai’s Program in Global Mental Health, breaks down how to deliver psychological first aid in a disaster setting in order to prevent post-disaster psychopathology.
Repeated Ketamine Infusions Reduce Symptom Severity in Chronic Post-Traumatic Stress Disorder
Repeated intravenous ketamine infusions significantly reduce symptom severity in individuals with post-traumatic stress disorder and the improvement is rapid and maintained for several weeks afterwards, according to a study conducted by ...
STOP COVID NYC: A Study Capturing City-Wide Coronavirus Symptoms and Mental Health Impacts
Laura Huckins, PhD, Assistant Professor of Psychiatry, and Genetics and Genomic Sciences, discusses a new app-based survey gathering data on New York City residents and their COVID-19-related symptoms in order to better understand transmission ...
CBD for Treating Opioid Addiction
Dr. Hurd’s latest study showed that CBD reduces cravings and anxiety in patients with heroin use disorder.
Intergenerational Effects of Trauma: A Biological Perspective
Rachel Yehuda, PhD, discusses how trauma from previous generations can affect descendants from an epigenetic standpoint.
New Frontiers for Depression: Deep Brain Stimulation, Esketamine, and the Immune System
“In five years, we expect to have a range of new treatments available targeting people with different forms of depression that work effectively, specifically for them.” –Eric Nestler, MD, PhD
An App-Based Game to Treat Depression
It looks and works like a game, but it acts like medicine—with no side effects.
From Genes to Treatment: Using Rare Genetic Disorders to Develop Novel Therapeutics
Dr. Kolevzon’s talk at the Seaver Autism Center’s 21st Annual Advances in Autism Conference.
Frontiers in Psychiatric Treatment: Addiction
The latest advances in addiction treatment from Tim Brennan, MD, MPH, Chief of Clinical Services for the Addiction Institute of Mount Sinai
Circuit Therapy for Neuropsychiatric Disorders
Martijn Figee, MD, PhD, Director of the Interventional Psychiatry Program, discusses circuit therapy for neuropsychiatric disorders
Borderline Personality Disorder: Neurocorrelates of the Social Emotional and Behavioral Disturbances
Harold Koenigsberg, MD, discusses neurocorrelates of the social, emotional, and behavioral disturbances in borderline personality disorder
Investigating the Environmental Etiology of Autism Spectrum Disorder
Magdalena Janecka, PhD, discusses the environmental etiology of autism spectrum disorder
The Future of Addiction Treatment: CBD, Big Data, Adolescents, and Telehealth
Eric Nestler, MD, PhD, moderates 20-minute talks from Yasmin Hurd, PhD; Xiaosi Gu, PhD; Kara Bagot, MD; and Timothy Brennan, MD, MPH. You'll hear about what we know, what we're learning, and how we're implementing what we learn about substance abuse
Stress, Resilience, and Digital Health Research in the Era of COVID-19
Mount Sinai has been on the forefront of trauma, stress, depression, and resilience research for decades. This virtual symposium covers the latest: what we know, and what we are learning that can equip us in addressing the pandemic’s psychological ...
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder
As part of The Friedman Brain Institute’s “FBI Cyber Series,” Rachel Yehuda, PhD, presents an exploration of the history and therapeutic use of MDMA
The Mount Sinai Center for Stress, Resilience and Personal Growth
Mental health experts from Mount Sinai discuss the stress on front-line workers due to COVID-19 and the creation of the Center.
The Impact of COVID-19 on Mothers and Babies
Veerle Bergink, MD, PhD, discusses mental health during pregnancy and the postpartum period during COVID-19, including potential long-term effects on the child’s brain.
Speech and Language Analysis for COVID-19
Cheryl Corcoran, MD, discusses how speech and language markers can be used to track physiology and psychiatric sequelae related to COVID-19 course together with other variables and biomarkers.